AST Asterias Biotherapeutics, Inc.

4.80
+0.05  (1.05%)
Previous Close 4.75
Open 4.80
Price To book 5.10
Market Cap 222.83M
Shares 46,422,000
Volume 213,208
Short Ratio 9.28
Av. Daily Volume 185,356

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 trial to be initiated 2017.
AST-VAC2
Non-small cell lung cancer (NSCLC)
Phase 1/2 six-month data due January 24, 2017. Interim data presented September 14, 2016.
AST-OPC1 SCiSTAR
Cervical spinal cord injury
Phase 2b planned for 2018.
AST-VAC1
Acute myeloid leukemia (AML)

Latest News

  1. Asterias Announces Conference Call to Discuss 6-month Efficacy Data from AST-OPC1 SCiStar Study
  2. Asterias Announces Successful Commencement of Operations at New GMP Manufacturing Facility for AST-OPC1
  3. Current report No 1/2017
  4. The Life Sciences Report Announces 19 Companies Selected for the 2017 Small-Cap Biotech Watchlist
  5. ETFs with exposure to Asterias Biotherapeutics, Inc. : December 27, 2016
  6. Is HC2 Holdings Inc (HCHC) A Good Stock To Buy?
  7. ETFs with exposure to Asterias Biotherapeutics, Inc. : December 8, 2016
  8. ETFs with exposure to Asterias Biotherapeutics, Inc. : November 28, 2016
  9. Asterias Biotherapeutics, Inc. :AST-US: Earnings Analysis: Q3, 2016 By the Numbers : November 23, 2016
  10. ASTERIAS BIOTHERAPEUTICS, INC. Financials
  11. ASTERIAS BIOTHERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements an
  12. Ryan Chavez Appointed Chief Financial Officer of Asterias Biotherapeutics
  13. ASTERIAS BIOTHERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statement
  14. Asterias Biotherapeutics Inc (AST) Stock Will Be A Monster Bull!
  15. ASTERIAS BIOTHERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report
  16. Asterias Biotherapeutics Reports Third Quarter Results and Accelerating Enrollment of AST-OPC1 SCiStar Phase 1/2a Study
  17. Asterias Biotherapeutics Inc (AST) Stock Rips Higher
  18. Drug Stocks' Q3 Earnings to Watch on Nov 14: ARGS, AST
  19. ASTARTA published interim report for the nine months of 2016
  20. Asterias Biotherapeutics Announces Treatment of First Spinal Cord Injury Patient with Maximum Dose of AST-OPC1 in SCiStar Clinical Trial